Risk of Venous Thromboembolism with Drospirenone in Combined Oral Contraceptive Products

@article{Sehovic2010RiskOV,
  title={Risk of Venous Thromboembolism with Drospirenone in Combined Oral Contraceptive Products},
  author={Naida Sehovic and Katherine P. Smith},
  journal={Annals of Pharmacotherapy},
  year={2010},
  volume={44},
  pages={898 - 903}
}
OBJECTIVE: To review primary literature regarding the risk of venous thromboembolism (VTE) in users of combined oral contraceptives (COCs) containing drospirenone compared to COCs containing other progestins. DATA SOURCES: A literature search of MEDLINE and EMBASE (1950-January 2010) was conducted using the following search terms: VTE, thrombosis, thromboembolism, COC, combined hormonal contraceptives, drospirenone, Yasmin, and Yaz. Additional references were retrieved from reference citations… 

Tables from this paper

Oral contraceptive use for the primary prevention of ovarian cancer.

There is insufficient evidence to recommend for or against the use of OCs solely for the primary prevention of ovarian cancer, and the harm/benefit ratio was much more favorable when protection against endometrial and colorectal cancers was added.

Two cases of venous sinus thrombosis in women taking the oral contraceptive pill, Yaz (dropirenone/ ethinyl estradiol), and review of the literature

The overall prognosis of CVT is favorable but, further research is needed to outline optimal treatment options including the duration of anticoagulation therapy and the role of thrombolytic therapy to prevent serious neurologic deficits.

Deep Vein Thrombosis due to Oral Contraceptive use in a Young Female

A case of thrombosis of both deep and superficial venous system following use of second generation COC for just 2 months is reported.

Drospirenone‐Containing Oral Contraceptives and Risk of Adverse Outcomes After Myocardial Infarction

  • C. KarabayG. Kocabay C. Kırma
  • Medicine
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • 2013
This study aimed to investigate the effect of Yasmin use on cardiovascular outcomes in patients with acute ST segment elevation myocardial infarction (STEMI) undergoing primary angioplasty.

Hematological Profile Changes Among Oral Contraceptive Users: A Narrative Review

The main goal of this review was to evaluate the hematologic profile alterations brought on by the use of oral contraceptives, and most of the oral contraceptive users had higher hemoglobin, platelet, and erythrocyte counts than non-users.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Differences in chemical structure, metabolism, pharmacokinetics, affinity, potency, and efficacy via steroid receptors, intracellular action, and biological and clinical effects confirm the absence of a class effect of progestogens.

Pulmonary embolism in young people. Trends in Germany from 2005 to 2011.

There is a disproportionally higher increase of young women hospitalised for pulmonary embolism as principal diagnosis in recent years in Germany, and the possible impact of hormonal contraception on this increase has to be further elucidated.

Estrogen and thrombosis: Controversies and common sense

  • T. Deloughery
  • Medicine
    Reviews in Endocrine and Metabolic Disorders
  • 2011
Clinicians can assess a patient’s risk of thrombosis by both composition of the agent and patients’ personal risk factors, and for women with bleeding disorders these prothrombotic changes can help decrease bleeding complications.

References

SHOWING 1-10 OF 23 REFERENCES

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

A high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives is confirmed, and many women do not use the safest brands.

Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study

Risks of venous thromboembolism was slightly increased in users of third generation oral contraceptives compared with users of second generation products and the need for clinical prudence is indicated but doctors and women seeking contraception should exercise informed choice.

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

This meta-analysis supports the view that thirdgeneration oral contraceptives are associated with an increased risk of venous thrombosis compared with second generation oral contraceptives, and cannot be explained by several potential biases.

Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate

Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect and predicts the risk of venous thrombosis.

Oral contraceptives and venous thromboembolism: old questions revisited

  • J. Dinger
  • Medicine
    Journal of Family Planning and Reproductive Health Care
  • 2009
The existing evidence continues to suggest that the risk of VTE attributable to COCs is primarily dependent on the dose of estrogen, and the likelihood of venous thromboembolism in third generation combined oral contraceptives is low.

Coagulation effects of oral contraception.

  • J. Bonnar
  • Medicine
    American journal of obstetrics and gynecology
  • 1987

Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin.

Yasmin is associated with venous thromboembolism, and an incidence rate has been calculated, but this may be subject to bias and should be interpreted with caution.